BridgeBio Pharma, Inc. <BBIO.O>: Wells Fargo raises target price to $102 from $98
BBIO•Related News
Moody’s upgrades Teva to investment-grade Baa3 rating
TEVA•
Magellan Copper and Gold Q2 net loss widens to $238,586; operating loss widens to $84,468
MAGE•
Protara Therapeutics Q2 net loss widens on higher expenses
TARA•
Trading platform eToro beats profit estimates, targets US growth with TradeZero buy
ETOR•
Theriva Biologics Q2 net loss narrows on lower R&D costs, expenses
TOVX•